245 First Street - 18th Floor
Fax: 617- 444-8405
About GENFIT CORP.Genfit is a biopharmaceutical company, listed on Alternext by Euronext™ Paris (ALGFT - FR0004163111) with headquarters in Lille, France and a US subsidiary in Cambridge, Massachusetts.
Through its world-renowned scientific expertise, particularly in the field of nuclear receptors, Genfit’s research efforts are focused on the discovery and development of new treatments mainly in the growing therapeutic areas of Cardiometabolic and Neurodegenerative disorders, such as prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity, and Alzheimer’s. Genfit uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments to address these major public health problems and their unmet medical needs.
Genfit has an original business model built on both proprietary internal programs and a strong track record of partner-supported programs and collaborations. This strategy allows the company to efficiently manage the risks associated with the internal programs, and at the same time build value for its shareholders. Genfit, on its own or in collaboration with its major pharmaceutical partners, has thus created a rich and diversified pipeline of drug candidates in pre-clinical and clinical development, as well as a broad intellectual property portfolio.
Genfit’s strong portfolio of therapeutic products, tools, and clinical biomarkers, together with its scientific expertise, have made the Company into a European biotechnology leader.
Parc Eurasanté – Lille Metropole
885 Avenue Eugene Avinee
Tel : +33 (0)3 2016 4000
Fax : +33 (0)3 2016 4001
175 articles with GENFIT CORP.
GENFIT: Therapeutic Potential Of Gft505 Is Demonstrated In The Treatment Of Cardiovascular Risk Associated With Pre-Diabetes
GENFIT: New Phase I Clinical Trials With High-Dose Confirm The Excellent Tolerance Of GFT505 In Healthy Volunteers
GENFIT Release: Xavier Guille des Buttes Elected Chairman of the Supervisory Board, Raphaël Darteil and Nathalie Huitorel Appointed as Members of the Management Board